A single dose, randomised, placebo-controlled, double-blind, 5-way
crossover (employing an incomplete block design), efficacy (including 24-h
pulmonary function tests) and safety comparison of Tiotropium/BI 54903
FDC ethanolic inhalation solution via Respimat® (doses of 1.23 μg/363.6 μg,
2.46 μg/363.6 μg or 4.93 μg/363.6 μg) versus free combination of Tiotropium
aqueous inhalation solution via Respimat® (doses of 0, 2.5 μg, 5 μg or 10
μg) plus BI 54903 ethanolic inhalation solution via Respimat® (dose of 363.6
μg ) in patients with asthma